recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 [Epub ahead of print].
Acknowledgements: This study was conducted thanks to an unrestricted grant from MSD.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.4730

AB0695 DOSE TAPERING OF INFIXIMAB IN PATIENTS WITH SPONDYLOARTHRITIS

M. Correyero, J.C. Nieto, C.M. González, A. López, R. González, C. Saenz, L. García-Montoya, F.J.L. Longo, I. Monteagudo. *Rheumatology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain*

Background: Infliximab have proven to be effective in spondyloarthritis. Previous studies suggest that patients in clinical remission may benefit from dose reduction or pharmacological tapering without relapse.
Objectives: To study the evolution of clinical activity and physical function in patients with spondyloarthritis, ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under Infliximab (IFX) tapering strategy.
Methods: This is a prospective single-centre observational study of patients diagnosed with AS and PsA treated with IFX (5 mg/kg/infusion) between January 1, 2012 and December 31, 2015. We included patients who achieved clinical remission or low activity index (expressed with BASDAI and BASFI) and decided to lower the dose of 5 to 4 mg/kg/infusion, maintaining the periodicity of the treatment in each patient. Demographic data (age, gender, time with IFX) daily activities, physical activity (BASDAI and BASFI) and laboratory data (ESR and CPR) were collected at the baseline visit prior to tapering, at the next infusion following dose reduction and the last infusion (between November 1st 2014 and December 31st, 2016).
Results: We included 18 patients (16 men) on IFX treatment with EA (16) or axial APs (2). The medians of age and time of evolution were 50.79 years (41.8–55.1) and 9.5 years (7.2–11.5), respectively. Table 1 shows the clinical and laboratory data obtained at the baseline visit, the next infusion and the last infusion. Fourteen patients (87.9%) continued with the dose of 4 mg/kg/infusion and are maintained in clinical remission. Four patients returned to the dose of 5 mg/kg/infusion due to loss of efficacy at dose reduction, with a mean follow-up of 17.6 months (17.0–19.1). Clinical remission was again achieved in the 4 patients, although one of them changed biological therapy due to loss of efficacy of IFX after 3 infusions with 5 mg/kg/infusion.

Table 1. Clinical and laboratory data during follow-up

	Baseline	Next Infusion	Last Infusion
BASDAI median (RI)	3,1 (1,45–4,45	4 (1,4–4,25)	4,1 (1,65–6,15)
BASFI median (RI)	2,8 (1,1–4,5)	3,6 (1,8–4,25)	2,8 (1–5)
ESR (mm/h) median (RI)	6,5 (3–11,25)	4,5 (3–11,5)	12,5 (6,5–16,75)
CPR (mg/dl) median (RI)	0,2 (0,2–0,55)	0,3 (0,1–0,4)	0,2 (0,1–0,72)

Conclusions: In our patients with spondyloarthritis dose reduction of IFX was well tolerated and safe, maintaining the clinical response measured by BASDAI and BASFI. In 3 out of 4 patients who worsened upon dose reduction, the 5 mg/kg/infusion dose recovered clinical remission.
References:
[1] Janta I et al. Clin Rheumatol. 2015;34: 935–42.
[2] Baraliakos X et al. RMD Open. 2016;2: e000272.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.6554

AB0696 RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS FIRST- OR SECOND-LINE BIOTHERAPIES FOR SPONDYLOARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)

M. Soubrier[1], B. Castagné[1], B. Pereira[2], A. Fan[1], T. Frayssac[1], M. Couderc[3], S. Malochet-Guinamand[1], S. Mathieu[1], Z. Tatar[1], A. Tournadre[3], J.-J. Dubost[1]. *[1]Rheumatology, C.H.U. HÔPITAL GABRIEL MONTPIED; [2]DRCI, CHU Gabriel Montpied; [3]Rheumatology, CHU Hopital Gabriel Montpied, Clermont-Ferrand, France*

Background: The use of tumour necrosis factor alpha (TNF-α) inhibitors – or anti-TNFs – has considerably improved the treatment of spondyloarthritis (SpA). The first three of these available anti-TNFs (infliximab, adalimumab, and etanercept) are the most widely used in the treatment of SpA. Their efficacy and safety have been demonstrated in extensive randomised controlled trials (RCTs).Nevertheless, the randomized studies were of short duration and included a selected population that differed from patients treated in daily practice
Objectives: To compare, in real-life settings, the retention rates of the initial anti-TNF treatment (etanercept [ETN], adalimumab [ADA],and infliximab [IFX]) used as first-line biotherapy for spondyloarthritis (SpA), and to evaluate treatment switches to another anti-TNF inhibitor in the event of treatment failure.
Methods: Monocentric retrospective cohort including all SpA patients starting an initial anti-TNF therapy between 2001 and 2015.
Results: Of the 249 SpA patients analysed (135 radiographic cases, 114 non-radiographic), 102 were given ETN, 62 ADA, and 85 IFX. In total, 103 discontinued treatment. The median retention duration was 69.7 months (17–∞) (ETN: 55.4 [17.6–94.6], ADA 57.6 [13.9–∞], and IFX: not reached). Retention was longer for IFX compared with ETN (HR=0.62 [0.39–0.99]) but non-significant compared with ADA (HR: 0.91 [0.56–1.48]). The percentage of patients continuing treatment after 5 years was 47% for ETN, 46% for ADA, and 62% for IFX. In multivariate analysis, the predictive factors for retention were a low BASDAI score (HR: 1.02 [1.01–1.04]), high CRP levels (HR 0.98 [0.97–0.99]), the concomitant use of disease-modifying therapy (HR: 0.4 [0.21–0.75]), and radiographic SpA (HR: 1.5 [1.0–2.52]). In total, 61 patients switched to another anti-TNF therapy. No difference was observed among the three anti-TNF therapies with regard to the median retention duration, but the retention rate was higher in the event of treatment switches from one monoclonal antibody to another.
Conclusions: The retention rate in SpA patients proved high, and retention for IFX was superior to that of ETN.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.3699

AB0697 IMPACT OF THE BASELINE BATH ANKYLOSING SPONDYLITIS RADIOLOGY HIP INDEX ON THE STRUCTURAL HIP JOINT PROGRESSION AFTER TNFα BLOCKING THERAPY IN SPONDYLOARTHRITIES PATIENTS

K. Maatallah[1], M. Sahli[1], I. Mahmoud[2], W. Hamdi[1], O. Saidane[2], M. Kchir[1], R. Tekaya[2], L. Abdelmoula[2]. *[1]Rheumatology, Kassab university hospital; [2]Rheumatology, Charles Nicolle university hospital, Tunis, Tunisia*

Background: One of the major goals of treatment of spondyloarthrites (SpA) is to prevent or slow the radiographic damage.The results of clinical trials raised expectations that TNFi are effective not only on clinical and biological parameters of the disease but may also have structural effect.
Objectives: We assessed whether the baseline Bath Ankylosing Spondylitis Radiology (BASRI) hip index had effect on structural hip progression under TNFα blockers in SpA patients with hip disease.
Methods: This was a multicentric longitudinal study including SpA patients (ASAS2009) with hip disease under TNF α blockers. Anteroposterior X-rays of the pelvis obtained at baseline were compared with X-rays obtained after 5 years [3–10] of continuous TNF α blockers treatment. Radiographic progression of the hip was evaluated by the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-h), scoring system (min 0 = no change, 1 = focal joint space narrowing, 2 = circumferential joint space narrowing >2 mm, 3 = circumferential joint space narrowing ≤2 mm or bone-on-bone apposition of <2 cm and max 4 = bone deformity or bone-on-bone apposition of ≥2 cm) and the hip joint space width (assessed by the average of measurements at three distinct sites between the acetabulum and femoral head)[1]. The median progression of the hip joint space was chosen as cut-off to define the structural evolution, it was 0.3mm. A good response of the hip was defined by a stabilization or a decrease of the hip joint space less than 0.3 mm (RH+).A poor response was defined by a decrease of the hip joint space >0.3mm (RH-).
Results: 48 patients were included (81% male). The average age was 40.7±11years. The mean age at the onset of the disease was 25.8±10 years. Hip involvement was bilateral in 77% of cases. At baseline, the mean BASRI hip index was 2±0.8. The BASRI hip score was 1 in 26%, 2 in 51%, 3 in 18% and 4 in 5% of patients. The average of hip joint space width at baseline was 3.4±1.2mm. Infliximab was the most prescribed TNFα blocker (48%) followed by Etanercept (37.5%) and Adalimumab (14.5%).After 5years, the mean BASRI hip index remained stable 2±0.8, the BASRI hip score was 1 in 23%, 2 in 50%, 3 in 14% and 4 in 13% (p=ns). The variation of hip joint space width was-0.294 mm (p=ns). 29 patients were RH+. The BASRI hip index 2±0.8 and 2.1±0.9 in RH+ and RH- patients respectively with no statistically significant difference.
Conclusions: According to our study the structural hip joint progression under TNFα blockers is not influenced by the baseline BASRI hip index.
References:
[1] Konsta M,Sfikakis PP, Bournia VK, Karras D, Iliopoulos A.Clin Rheumatol (2013) 32:1229–1232.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.6459

AB0698 COMPLEMENTARY AND ALTERNATIVE MEDICINE USAGE AND ASSOCIATED FACTORS IN ANKYLOSING SPONDYLITIS: PRELIMINARY RESULTS OF A CROSS-SECTIONAL STUDY

F.I. Cinar[1], O. Ozdemir[2], S. Yilmaz[3], N. Ozen[4], G. Bagcivan[5], I. Aydoğan[6], A.G. Yalcin[6], E. Tekgoz[3], M. Cinar[3]. *[1]Gulhane School of Nursing, University of Health Sciences; [2]Department of Nursing, Ankara Yildirim Beyazit University, Faculty of Health Sciences; [3]Department of Internal Medicine, Division of Rheumatology, University of Health Sciences, Gulhane Medical Faculty, Ankara; [4]University of Health Sciences, Okmeydani Training and Research Hospital, Kasimpasa Building, Istanbul; [5]Department of Internal Medicine; [6]Division of Rheumatology, Gulhane Training and Research Hospital, Ankara, Turkey*

Background: Several surveys indicate that the complementary and alternative medicine (CAM) use is especially prevalent in patients with chronic painful